Advanced Proteomics Masterclass: Techniques and Applications in Precision Medicine The event aims to introduce and explore APTAMARKER, an advanced aptamer-based technology platform developed by Dr. Gregory Penner and his team at Neoventures Biotechnology. This platform… Aptamarker Masterclass, PMFG Summit / Nov 30 2025/Doha,Qatar
Join us at BIO-Europe Fall 2025 We’re pleased to share that Dr. Gregory Penner, Chief Scientific Officer at NeoVentures Biotechnology Europe, will be participating in BIO-Europe Fall 2025, taking place November 3-5 in Vienna, Austria.… NeoVentures Biotechnology Europe at Bio-Europe Fall 2025
NeoVentures Biotechnology Europe Partners with Ombion Biomarker discovery has been and remains a key to advancing treatments in healthcare. The majority of the science in this area has relied on antibody production with the introduction… NeoVentures Biotechnology Europe partners with Ombion
NeoVentures Biotechnology Europe has joined NVIDIA Inception, a program designed to help startups evolve faster through cutting-edge technology and access to the latest technical resources from NVIDIA. At NVB Europe, we’ve developed the Aptamarker Platform,… NVB Europe has joined NVIDIA Inception
The Institut de Recherche pour le Développement, Délégation Régionale Occitanie (IRD-Montpellier), and NeoVentures Biotechnology Europe (NVBE) are proud to announce a strategic partnership to co-develop the NVBE Aptamarker platform for single-cell proteomics. The Institut de… Strategic Partnership with IRD-Montpellier
NeoVentures Biotechnology Europe will be attending BIO-Europe Spring.
Abstract: The traditional approach to biomarker discovery for any pathology has been through hypothesis-based research one candidate at a time. The objective of this study was to develop an agnostic approach for the simultaneous screening… First human test application of the Aptamarker Platform to screen plasma for all possible biomarkers simultaneously.
NeoNeuro, announced today that it has received an investment from the Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator, an initiative that aims to fast-track the development of novel biomarkers for the early detection of Alzheimer’s disease and… NeoNeuro receives investment from the Alzheimer Drug Discovery Foundation ( ADDF)
ABSTRACTIntroduction: This review is focused on the methods used for biomarker discovery for Alzheimer’sdisease (AD) in blood rather than on the nature of the biomarkers themselves.Areas covered: All biomarker discovery programs explicitly rely on contrasts… Review paper: blood based diagnostics of Alzheimer’s disease.
The act of selecting aptamers against blood serum leads to deep libraries of oligonucleotide sequences that bind to a range of epitopes in blood. In this study we developed an enriched aptamer library by performing… Aptamers as biomarkers for neurological disorders
